NAP Peptide [211439-12-2]
N0160
Estimated Purity≥95%
Product group Chemicals
Overview
- SupplierLKT Laboratories
- Product NameNAP Peptide [211439-12-2]
- Delivery Days Customer7
- CertificationResearch Use Only
- Estimated Purity≥95%
- FormatSoluble in DMSO.
- Scientific DescriptionOctapeptide derived from activity-dependent neuroprotective protein (ADNP).; Davunetide
- Storage Instruction-20°C
- UNSPSC12352200
References
- Scuderi S, D'Amico AG, Castorina A, et al. Davunetide (NAP) Protects the Retina Against Early Diabetic Injury by Reducing Apoptotic Death. J Mol Neurosci. 2014 Feb 2. [Epub ahead of print]. PMID: 24488575. Jouroukhin Y, Ostritsky R, Assaf Y, et al. NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: protection against impairments in axonal transport. Neurobiol Dis. 2013 Aug;56:79-94. PMID: 23631872. Gold M, Lorenzl S, Stewart AJ, et al. Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy. Neuropsychiatr Dis Treat. 2012;8:85-93. PMID: 22347799. Sharma NK, Sethy NK, Meena RN, et al. Activity-dependent neuroprotective protein (ADNP)-derived peptide (NAP) ameliorates hypobaric hypoxia induced oxidative stress in rat brain. Peptides. 2011 Jun;32(6):1217-24. PMID: 21453737. Merenlender-Wagner A, Pikman R, Giladi E, et al. NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse--a microtubule-deficient model of schizophrenia. Peptides. 2010 Jul;31(7):1368-73. PMID: 20417241.